# Dupilumab in Severe Chronic Hand Eczema

> **NCT04512339** · PHASE2 · UNKNOWN · sponsor: **University Medical Center Groningen** · enrollment: 30 (estimated)

## Conditions studied

- Hand Eczema

## Interventions

- **DRUG:** Dupilumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04512339
- **Lead sponsor:** University Medical Center Groningen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-01
- **Primary completion:** 2022-08
- **Final completion:** 2022-08
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-08-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04512339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04512339, "Dupilumab in Severe Chronic Hand Eczema". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04512339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*